Drug Profile
Research programme: antibacterials - Deinove/sanofi-aventis
Latest Information Update: 07 Feb 2019
Price :
$50
*
At a glance
- Originator Morphochem AG; sanofi-aventis
- Developer Morphochem AG; Sanofi
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Bacterial infections
Most Recent Events
- 15 Dec 2006 Suspended - Preclinical for Bacterial infections in Europe (unspecified route)
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis